Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases.

TitleCamelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases.
Publication TypeJournal Article
Year of Publication2010
AuthorsTremblay JM, Kuo C-L, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB
JournalToxicon
Volume56
Issue6
Pagination990-8
Date Published2010 Nov
ISSN1879-3150
KeywordsAnimals, Antibodies, Binding Sites, Antibody, Botulinum Toxins, Camelids, New World, Clostridium botulinum, Immunoglobulin Heavy Chains, Inhibitory Concentration 50, Neurons, Neurotoxins, Peptide Hydrolases, Peptide Library, Protease Inhibitors
Abstract

Botulinum neurotoxins (BoNTs) function by delivering a protease to neuronal cells that cleave SNARE proteins and inactivate neurotransmitter exocytosis. Small (14 kDa) binding domains specific for the protease of BoNT serotypes A or B were selected from libraries of heavy chain only antibody domains (VHHs or nanobodies) cloned from immunized alpacas. Several VHHs bind the BoNT proteases with high affinity (K(D) near 1 nM) and include potent inhibitors of BoNT/A protease activity (K(i) near 1 nM). The VHHs retain their binding specificity and inhibitory functions when expressed within mammalian neuronal cells as intrabodies. A VHH inhibitor of BoNT/A protease was able to protect neuronal cell SNAP25 protein from cleavage following intoxication with BoNT/A holotoxin. These results demonstrate that VHH domains have potential as components of therapeutic agents for reversal of botulism intoxication.

DOI10.1016/j.toxicon.2010.07.003
Alternate JournalToxicon
PubMed ID20637220
PubMed Central IDPMC2946066
Grant ListN01AI30050 / AI / NIAID NIH HHS / United States
R21 AI088489 / AI / NIAID NIH HHS / United States
U54 AI057159 / AI / NIAID NIH HHS / United States
N01-AI-30050 / AI / NIAID NIH HHS / United States
Related Institute: 
Molecular Imaging Innovations Institute (MI3)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065